Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

The meeting of the American Society of Oncology focused on optimizing immunotherapy and other advanced treatments for ...

New phase 3 data show that sacituzumab govitecan plus pembrolizumab delays cancer progression in PD-L1-positive metastatic ...

SMMT's HARMONi trial shows PFS benefits for ivonescimab in EGFR-mutant NSCLC, but lack of proven overall survival raises ...

AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Two-Part Dose Escalation and Expansion Trial Will Evaluate Efficacy and Safety of BYON4228 Alone and in Combination with Pembrolizumab NIJMEGEN, The ...

Almost one in five patients with advanced melanoma survived for five years after receiving lifileucel, with tumours shrinking ...

The trial evaluated the combination of GSK’s Jemperli and Zejula as a first-line therapy for stage III and IV epithelial OC.

The trial, which was funded by a National Institute for Health and Care Research (NIHR) Health Technology Assessment grant, ...

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

The ADC market was valued at $8.6bn in 2023, with it forecast to exceed $45bn by 2030, according to analysis by GlobalData.